Eleonora Farinazzo Selected Research

secukinumab

1/2020

Secukinumab-induced subacute cutaneous lupus erythematosus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eleonora Farinazzo Research Topics

Disease

1	Atopic Dermatitis (Atopic Eczema) 05/2022
1	Inflammation (Inflammations) 05/2022
1	Prurigo 05/2022
1	Halo Nevus 12/2021
1	Neoplasm Metastasis (Metastasis) 12/2021
1	Nevus (Nevi) 12/2021
1	Vitiligo 12/2021
1	Melanoma (Melanoma, Malignant) 12/2021
1	Thrombophilia 01/2021
1	Chilblains (Chilblain) 01/2021
1	Infections 01/2021
1	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2020
1	Actinic Keratosis 06/2020
1	Cutaneous Lupus Erythematosus 01/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2019

Drug/Important Bio-Agent (IBA)

2	pembrolizumabIBA 12/2021 - 11/2019
1	CytokinesIBA 05/2022
1	dupilumabIBA 05/2022
1	Monoclonal AntibodiesIBA 05/2022
1	Interleukin-4 Receptor alpha SubunitIBA 05/2022
1	InterleukinsIBA 05/2022
1	Interleukin-13IBA 05/2022
1	trametinibIBA 12/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2021
1	dabrafenibIBA 12/2021
1	Interferon Type IIBA 01/2021
1	atezolizumabIBA 09/2020
1	secukinumabIBA 01/2020

Therapy/Procedure

2	Therapeutics 12/2021 - 06/2020
1	Immunotherapy 12/2021